Overview

A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)

Status:
Recruiting
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
To learn if adding 1 year of therapy with pembrolizumab can help to continue to control RCC after radiation therapy.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Cancer Prevention Research Institute of Texas
Merck Sharp & Dohme LLC
Treatments:
Pembrolizumab